Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

A number of other brokerages have also recently issued reports on CTLT. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $63.40.

Catalent Stock Performance

Shares of CTLT opened at $63.48 on Friday. Catalent has a 52-week low of $41.15 and a 52-week high of $63.50. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $11.52 billion, a PE ratio of -28.09, a P/E/G ratio of 2.70 and a beta of 1.15. The company has a 50-day simple moving average of $60.89 and a 200-day simple moving average of $59.56.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the company posted ($0.10) EPS. Equities research analysts predict that Catalent will post 0.78 earnings per share for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Catalent by 1.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock worth $1,179,000 after buying an additional 220 shares during the period. Crossmark Global Holdings Inc. raised its holdings in shares of Catalent by 2.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock worth $553,000 after purchasing an additional 229 shares during the period. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Catalent by 3.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock worth $432,000 after purchasing an additional 278 shares during the period. GAMMA Investing LLC lifted its stake in shares of Catalent by 26.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock valued at $79,000 after purchasing an additional 278 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC grew its holdings in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.